All News

In this first installment of UrologyTimes.com's new video section, called ‘Y’tube, we present videos from high-volume prosthetic surgeons performing inflatable penile prosthesis (IPP) placement and discussing diagnosis and management of ED. William O. Brant, MD, offers the following general commentary about these procedures, as well as specific comments in the text accompanying each individual video.

In these videos, H. Ballentine Carter, MD, discusses the evidence supporting active surveillance, and Leonard S. Marks, MD, and colleagues outline which men are good candidates for surveillance.

Results of a study that included approximately 50,000 patients point to an association between kidney stones and incident cardiovascular disease and stroke.

Men who eat over 10 portions a week of tomatoes have an 18% lower risk of developing prostate cancer, according to a newly published study from the United Kingdom.

As it becomes apparent that more prostate cancers are clinically insignificant than previously believed, the role of active surveillance in the management of men with low-risk prostate cancer merits expansion.

This letter to the editor is in response to an editorial by J. Stuart Wolf, Jr., MD (“Robotic radical nephrectomy: Really?,” July 2014, page 6). The editorial concerned the article, “Use of robotic RN rising, despite unclear advantages” (July 2014, page 9).

Steven A. Kaplan, MD, introduces #LetsTalkMensHealth, a novel new section in Urology Times focused on men’s health.

Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.

Transrectal ultrasound-guided prostate biopsy is associated with a rising rate of hospitalization for urinary tract infection, new study results indicate.

Presentations of phase III data at the American Society of Clinical Oncology annual meeting in Chicago further support the conclusion that the oral androgen receptor inhibitor enzalutamide (XTANDI) addresses an unmet therapeutic need for metastatic castration-resistant prostate cancer in the pre-chemotherapy setting.

A recent study confirms that treatment choices for localized prostate cancer are not stagnant but continue to evolve, writes Leonard G. Gomella, MD.

A retrospective evaluation to determine adherence to the AUA clinical practice guideline for the management of lower urinary tract symptoms/BPH among urologists practicing in an academic setting found generally positive results, but with room for improvement, researchers reported at the AUA annual meeting in Orlando, FL.

The question of what role urologists should play in managing hormone-resistant prostate cancer is "controversial," says Kenneth Jacobsohn, MD.

In this interview, Stacy Loeb, MD (@LoebStacy), discusses why urologists should participate in Twitter, how it can benefit your daily practice, and some practical “dos and don’ts.”

Sexual function in men with lower urinary tract symptoms/BPH generally declines over time whether or not they are treated with medication. However, the magnitude of worsening differs depending on the treatment received, according to findings from the Medical Therapy of Prostatic Symptoms study.

Photoselective vaporization of the prostate is non-inferior to transurethral resection of the prostate in men with benign prostatic obstruction, researchers reported at the European Association of Urology annual congress in Stockholm, Sweden.

Use of surgery has increased steadily among all men with clinically localized prostate cancer, and in those with low-risk disease, brachytherapy utilization has declined.

As a number of common urologic surgeries have shifted from the inpatient to outpatient setting, potentially preventable deaths have increased following complications, the authors of a recently published study reported.

A significant number of older men with limited life expectancy continue to undergo routine prostate cancer screening, researchers say.

In this article, Robert A. Dowling, MD, discusses practical aspects of a work flow analysis in your office, including its relationship with health information technology and some helpful resources and tools.

The Centers for Medicare & Medicaid Services proposed changes to Medicare payment cover the Physician Quality Reporting System, value-based payment modification, potential relative value unit changes, targeted codes, and a change in global for future years, among other items.

A July 29 report by the Institute of Medicine on reforming the nation’s graduate medical education program has struck a nerve with the AUA and other medical societies by questioning the seriousness of continuing physician shortages in the United States.

When considering purchase of a disability insurance policy, it’s important to have an exact understanding of the language being used in the policy.

The House of Delegates, the democratic policy-making body of the American Medical Association, meets twice a year to establish broad policy on health, medical, professional, and governance matters. As in previous years, several resolutions from this June’s meeting were of key interest to urologists.

The Androgen Study Group has called upon the Journal Oversight Committee to investigate what it deemed violations of “accepted standards of medical journal ethics and editorial integrity” by JAMA.

Data from 2 years of prospective follow-up in a multinational study show that the prostatic urethral lift (PUL [UroLift System, Neotract, Inc., Pleasanton, CA]) is a safe procedure that provides durable, clinically meaningful improvement of lower urinary tract symptoms due to BPH, reported Claus G. Roehrborn, MD, at the AUA annual meeting in Orlando, FL.

As health care providers, our prime directive is to help our patients. Unfortunately, this altruism does not exempt us from the possibility of a violent act by a patient against us or our staff.

Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.